Actelion seeks CFDA approval for Zavesca in ultra-rare Niemann-Pick Type C
By Cornelia Zou
Wednesday, January 8, 2014
HONG KONG – Swiss biopharmaceutical Actelion Ltd. is seeking regulatory approval in China for its Zavesca (miglustat) to treat Niemann-Pick Type C (NPC), a rare disease for which there is little information and no treatment available in the country.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.